Vaccine Design and Testing – Products

Fluid and cold chain management expert Single Use Support has opened a subsidiary in Lexington, Massachusetts. Equipped with a product showroom, the office will also serve as a base for increased US staff.

AMSBIO has expanded its range of products and services dedicated to assisting scientists diversify their preclinical models effectively to help bridge the gender discrepancy gap in many areas of research.

At the 2023 Grand Challenges Annual Meeting, Bill Gates, announced new investments to advance access to mRNA research and vaccine manufacturing technology that will support low- and middle-income countries.

Partnership between two Canadian life sciences leaders offers a commercial GMP manufacturing solution for Acuitas’ licensed partners developing promising next generation therapies.

This application note demonstrates the successful identification of two low-abundance monoclonal antibodies using next-generation protein sequencing.

Takara Bio Europe announced the launch of new High Quality grade mRNA production enzymes "T7 RNA polymerase, HQ" and "Pyrophosphatase (inorganic), HQ" suitable for pre-clinical and process development in mRNA vaccine and therapeutic manufacturing.

Learn more about influenza vaccine solutions!

The National Institutes of Health selected Exothera S.A. therapeutics to develop the manufacturing process for NIH’s intranasal vaccine against SARS-CoV-2.

New ready-to-ship xGen™ NGS solution will enable researchers to combat challenging diseases of today and prepare for the next pathogen of tomorrow.

Absolute Biotech has announced the reintroduction of SCICONS™ dsRNA antibodies, used to detect dsRNA intermediates of a wide range of viruses, including chikungunya, dengue, hepatitis, rabies, rhinovirus, polio and swine fever.